Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Seres Therapeutics

11/03/2025 13:01

Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show a fall in quarterly revenue when it reports  results on March 13 for the period ending December 31 2024

​LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of 20 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Seres Therapeutics Inc is $1.25​, above​ its last closing price of $0.73. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.24
-0.25
-0.38
Missed
-54.8
Jun. 30 2024
-0.27
-0.27
-0.22
Beat
19.7
Mar. 31 2024
-0.35
-0.34
-0.27
Beat
20.8​
Dec. 31 2023
-0.40
-0.50
-0.32
Beat
35.6
​​Sep. 30 2023
-0.49
-0.50
-0.37
Beat
26.2
Jun. 30 2023
0.53
0.53
0.36
Missed
-32.6​
Mar. 31 2023
-0.56
-0.55
-0.57
Missed
-3.8
Dec. 31 2022
-0.30
-0.46
-0.54
Missed
-16.1

This summary was machine generated March 11 at 13:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)